Navigation Links
Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
Date:3/26/2008

ents currently approved for these indications."

NuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation retinoid and rexinoid compounds for application in oncology (treatment, prevention and adjunctive supportive therapy) and other highly prevalent diseases. The company's lead compounds are NRX4204, a highly specific, next-generation rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer and a RAR agonist for the treatment of acute leukemia. Based in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this news release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the fact that the Company is engaged in early stage research and does not expect to obtain any revenues for several years and other risks as detailed from time to time in the Company's registration statement and reports and filings with the Securities and Exchange Commission. All forward-looking statements, if any, in this news release represent the Company's judgment as of the date of this news release. The Company disclaims, however, any intent or obligation to update forward-lookin
'/>"/>

SOURCE NuRx Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
2. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
3. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
4. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
5. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
6. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
10. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... peer-reviewed publication of the results of the Company,s ... preservative-free eye drops) for the treatment of dry ... (CAE ® ) model.  The exploratory study was ... were previously disseminated by the Company in a ...
(Date:5/22/2015)... -- The Mesothelioma Victims Center is incredibly passionate about ... best possible compensation, and they are also extremely focused ... caused by exposure to asbestos or their family ... options such as a recent possible medical breakthrough. For ... anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
(Date:5/22/2015)... May 22, 2015 According to ... by Product (Consumables, Instruments, Services), by Test Type (Indirect, ... Flow Cytometry), by End Users - Global Forecast to ... is expected to reach $736.85 Million by 2020 from ... 10.25%. Browse 71 market data Tables ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4
(Date:5/22/2015)... According to Berks and Beyond , Pennsylvania has been ... 2,500 confirmed drug deaths, as reported on May 7th. The ... stemming from legal and illegal drug use in 2014. As ... to fatal overdoses or other drug related deaths. The city ... most rife with drug related deaths. The city, along with ...
(Date:5/22/2015)... West Hollywood, CA (PRWEB) May 22, 2015 ... at Sunset Plaza Dental announces that they ... in cosmetic, restorative and other dental treatments. At ... that interest them. Questions regarding what certain treatments ... can also be covered during this initial appointment. ...
(Date:5/22/2015)... 22, 2015 Gateway Building Concepts is ... The services the company specialize in include decks, additions, ... pool houses and much more. , The redesigned ... owner of the company. It includes two geometrical lines ... was thought out to be used with many things ...
(Date:5/22/2015)... May 22, 2015 Medivo, Inc., a leader ... Rates and Genotype Results in ‘Baby Boomers’ Screened for HCV ... Nationwide Lab Test Database” at Digestive Disease Week, May 16-19, ... Affairs and Analytics team members Carol Smyth, MB; Jason Bhan, ... Parker, MSI, along with Nancy Reau, MD from the University ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 sweetFrog Enterprises, LLC. ... in Jacksonville, Texas. Jacksonville is now the 16th sweetFrog store ... chain was listed as #22 on the Inc. 500 list ... have lived and worked in East Texas for 20 years ... Anderson, owner of the Jacksonville, and nearby Palestine, sweetFrog locations. ...
Breaking Medicine News(10 mins):Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2
... , SC AG McMaster to Address Constitutionality of "Cornhusker ... Jan. 11 South Carolina Attorney General Henry McMaster will ... of the health care reform bill being considered by Congress, ... 2:00 p.m. on Wednesday, January 13th, in the Zenger Room, ...
... , HARRISBURG, Pa., Jan. 11 The Department of Health vaccinated ... on Jan. 8 and 9. The department urges anyone who has ... for people to get vaccinated even though flu activity is currently ... we will have a third wave of H1N1 flu, so it ...
... , FAIRVIEW, Pa., Jan. 11 ... manufacturer of custom electronic products and systems, today reported results for ... , For the fourth quarter of fiscal 2009, the Company reported ... sales of $34.1 million, compared to net income of $2.5 million ...
... workouts protected cognitive function of older adults in two ... appears to help prevent and improve mild cognitive impairment, ... who did moderate physical activity in midlife or later ... that six months of high-intensity aerobic exercise improved cognitive ...
... to get a clot-dissolving drug than on weekdays, study found ... to a hospital on a weekend are more likely to ... on a weekday, a study finds. , It,s an unexpected ... showing that aggressive treatment for heart attacks was more likely ...
... WINSTON-SALEM, N.C. Researchers at Wake Forest University Baptist ... variant associated with aggressive prostate cancer, proving the concept ... combination with other factors to guide treatment decisions. ... 11-15) in the Proceedings of the National Academy ...
Cached Medicine News:Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 2Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 3Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 4Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 5Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 6Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 7Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 8Health News:Spectrum Control Reports Fourth Quarter and Annual Profit 9Health News:Exercise May Stave Off Mental Decline 2Health News:More Aggressive Treatment for Weekend Stroke 2Health News:More Aggressive Treatment for Weekend Stroke 3Health News:Genetic variant associated with aggressive form of prostate cancer 2
Headquartered in Burlington, North Carolina, LabCorp has more than 23,500 employees and offers more than 4,400 clinical tests ranging from routine blood analyses to the most sophisticated molecular d...
... Clinical Reference Laboratories at National Jewish ... general and specialized testing for clients ... diagnostic reference laboratories, they provide comprehensive, ... areas of immunology and flow cytometry, ...
Disposable Microscissors: Horizontal Curved Microscissors...
Sharp tipped illuminated scissors with a curvature of 12 mm to follow the contour of the retina. For cutting in the plane parallel to the retina, cutting membranes adherent to the retinal surface and...
Medicine Products: